MagArray Launches Lung Cancer Test, Hitachi an Investor

MagArray-mr-813-reader-unit-300x241MagArray, a developer of advanced medical diagnostics using magnetic nanosensor technology, has announced the US market launch of REVEAL Lung Nodule Characterization, a blood test to assess the risk of lung cancer in current smokers. MagArray’s proprietary technology has significant potential to address a large area of unmet need in the risk assessment of lung cancer, said Luis Carbonell, CEO. “We are proud to offer REVEAL Lung Nodule Characterization as an application of our technology to aid clinicians in their assessment of indeterminate lung nodules in current smokers,” said Carbonell.

MagArray develops and commercializes magnetic nanosensor technology that was developed under the direction of Shan X. Wang, PhD, co-founder of MagArray and a professor at Stanford University. “There are a number of challenges clinicians face when effectively and efficiently diagnosing lung cancer,” Dr. Wang commented. “Our research team is honored to make our technology available to clinicians to potentially impact diagnosis and treatment in a meaningful way.”

According to the company, in current lung cancer risk assessment protocols, it is quite common to have lung nodules detected through a CT scan for which the clinician has the difficult task of distinguishing between benign and malignant nodules. The American College of Chest Physicians guidelines for lung nodule management states that it is nevertheless important to estimate the clinical probability of malignancy before ordering imaging tests or invasive biopsy procedures. The new test is designed to help pulmonologists identify lung nodules that have a high probability of being benign, aiming to reduce costly and invasive procedures.

Earlier, in September, Hitachi High-Technologies Corporation announced that it would invest in the start-up and operation of MagArray’s diagnostic testing service. Future plans called for MagArray to develop next-generation, high-throughput equipment, consumables, and other products for the CLIA lab testing service business. Hitachi High-Tech has made the field of biotechnology and healthcare its priority. Amid a recent increase in demand for personalized healthcare that provides optimal medical treatment for each individual patient in this field, there are strong expectations for developments in cancer therapy and other areas, said MagArray. In the U.S., there is a system for conducting clinical testing accredited by Clinical Laboratory Improvement Amendments to ensure test quality in laboratory, the company explained. CLIA labs provide advanced clinical testing mainly on molecular and unique biomarkers. At the time, Hitachi High-Tech said that its corporate business vision in the biotechnology and medical system area is to aim to be a global player in all in vitro diagnostic businesses. To this end, the company is strengthening its existing businesses while aggressively engaging in strategic investments.

For more information visit